title: Relative binding affinity of novel steroids to androgen receptors in hamster prostate.
abstract: The in vivo and in vitro antiandrogenic activity of four aromatic esters 10a-10d, one aliphatic ester 10e based on the pregna-4,16-diene-6, 20-dione structure and two aromatic 17c, 17d and two aliphatic valeroyloxy esters 17a, 17b based on the more saturated 4-pregnene-6,20-dione skeleton was examined. The biological activity of steroids 9, 10a-10e and 17a-17d, was determined using prostate glands from gonadectomized adult male golden hamsters. In the in vitro studies, the relative binding affinity of these steroids to cytoplasmic androgen receptor (AR) of hamster prostate was determined from, the corresponding IC50 values obtained from the competitive binding plots. The standards dihydrotestosterone (DHT) and cyproterone (CA) acetate used have displaced [3H]DHT from the AR with an IC50 value of 3.2 and 4.4 nM respectively. All steroidal compounds synthesized in this study showed a binding affinity for the androgen receptor, present in the cytosol from prostate hamster; compounds 10a-10c showed the highest affinities for this receptor. The in vivo experiments showed that all steroidal derivatives were subcutaneously active, since they decreased the weight of the prostate gland in gonadectomized hamsters treated with DHT, and are antagonists for the androgen receptor since they block the DHT-induced prostate weight gain. The derivatives having the more conjugated 4,16-pregnadiene-6, 20-dione system (10a-10c) exhibited a higher antiandrogenic activity than the corresponding steroids (17a-17d) based on the more saturated 4-pregnene-6,20-dione system.
authors.affiliation: Department of Biological Systems and Animal Production, Metropolitan University-Xochimilco, Mexico DF, Mexico. marisa@correo.xoc.uam.mx
authors.forename: M
authors.initials: M
authors.lastname: Cabeza
authors.forename: I
authors.initials: I
authors.lastname: Heuze
authors.forename: M
authors.initials: M
authors.lastname: Sánchez
authors.forename: E
authors.initials: E
authors.lastname: Bratoeff
authors.forename: E
authors.initials: E
authors.lastname: Ramírez
authors.forename: A
authors.initials: A
authors.lastname: Rojas
authors.forename: A
authors.initials: A
authors.lastname: Orozco
authors.forename: A
authors.initials: A
authors.lastname: Mungía
authors.forename: G
authors.initials: G
authors.lastname: Agustín
authors.forename: L
authors.initials: L
authors.lastname: Cuatepotzo
authors.forename: C
authors.initials: C
authors.lastname: Gonzalez
authors.forename: S
authors.initials: S
authors.lastname: Palma
authors.forename: D
authors.initials: D
authors.lastname: Padilla
authors.forename: V
authors.initials: V
authors.lastname: Perez
authors.forename: G
authors.initials: G
authors.lastname: Jimenez
mesh_terms: D000726:Androgen Antagonists / Q000138:chemical synthesis / Q000378:metabolism* / Q000494:pharmacology; D059002:Androgen Receptor Antagonists; D000818:Animals; D006224:Cricetinae; D008297:Male; D008647:Mesocricetus; D011467:Prostate / Q000187:drug effects* / Q000378:metabolism; D011485:Protein Binding / Q000187:drug effects* / Q000502:physiology; D011944:Receptors, Androgen / Q000378:metabolism*; D013256:Steroids / Q000138:chemical synthesis / Q000378:metabolism* / Q000494:pharmacology
chemical_list: D000726:Androgen Antagonists; D059002:Androgen Receptor Antagonists; D011944:Receptors, Androgen; D013256:Steroids